Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03220425 | Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes. | PHASE3 | COMPLETED | 752 | — | — | Feb 1, 2001 | Nov 12, 2001 | Jul 18, 2017 | 93 | Australia, Belgium +8 |
| Arm | Type | Description |
|---|---|---|
| Insulin detemir | EXPERIMENTAL | - |
| NPH insulin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Insulin detemir | DRUG | - |
| NPH insulin | DRUG | - |
Inclusion Criteria: * Signed and dated informed consent obtained before any trial-related activities * Type 1 diabetes diagnosed and classified according to aetiology * Duration of type 1 diabetes equal to or more than 12 months * Glycosylated haemoglobin less than or equal to 12 percent based on a...